Chemical Name |
GP531 |
CAS Number |
142344-87-4 |
MDL Number |
MFCD00910974 |
Molecular Formula |
C16H21N5O4 |
Molecular Weight |
347.37 |
Introduction of 142344-87-4 :
GP531 is a potent, second-generation adenosine regulating agent, is pharmacologically silent under basal conditions but increases localized endogenous adenosine during ischemia. IC50 & Target: Adenosine Receptor[1] In Vivo: Low-dose GP531 reduces infarct size by 34% compared with vehicle and reduces the extent of the anatomic no-reflow zone by 31% compared with vehicle. Infarct size and zone of no-reflow in the high dose are reduced by 22% and 16%, respectively. GP531 does not affect hemodynamics or blood flow. GP531 is effective at the lower dose in reducing the severity of ischemic/reperfusion injury, without inducing the adverse hemodynamic effects associated with adenosine administration such as bradycardia and hypotension[1]. GP531 infusion has no effect on heart rate or mean aortic pressure but significantly decreases left ventricular end-diastolic pressure, end-diastolic volume, end-systolic volume and end-diastolic wall stress. GP531 significantly increases left ventricular EF, deceleration time of early mitral inflow velocity and the slope of end-systolic PVR without increasing MVO2[2].
Purity |
NLT 98% |
Storage |
at 20ºC 2 years |
*The above information is for reference only.